Zacks Research Issues Positive Forecast for TEVA Earnings

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) – Equities research analysts at Zacks Research upped their Q2 2026 earnings per share estimates for shares of Teva Pharmaceutical Industries in a research report issued to clients and investors on Monday, December 8th. Zacks Research analyst Team now anticipates that the company will post earnings of $0.61 per share for the quarter, up from their previous forecast of $0.60. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.50 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries’ Q4 2026 earnings at $0.77 EPS and Q3 2027 earnings at $0.83 EPS.

Other equities research analysts have also issued reports about the stock. The Goldman Sachs Group increased their target price on shares of Teva Pharmaceutical Industries from $28.00 to $31.00 and gave the stock a “buy” rating in a report on Monday. JPMorgan Chase & Co. upped their price objective on Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the stock an “overweight” rating in a research report on Thursday, November 6th. UBS Group lifted their target price on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. Wall Street Zen raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 11th. Finally, Scotiabank began coverage on Teva Pharmaceutical Industries in a research report on Friday, December 5th. They issued a “sector outperform” rating and a $35.00 price target on the stock. Three investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $30.25.

Teva Pharmaceutical Industries Trading Up 4.1%

NYSE TEVA opened at $29.74 on Thursday. The firm has a 50 day simple moving average of $23.03 and a 200-day simple moving average of $19.44. The company has a debt-to-equity ratio of 2.31, a quick ratio of 0.82 and a current ratio of 1.11. Teva Pharmaceutical Industries has a one year low of $12.47 and a one year high of $29.80. The firm has a market cap of $34.10 billion, a price-to-earnings ratio of 49.56, a PEG ratio of 1.53 and a beta of 0.67.

Insider Transactions at Teva Pharmaceutical Industries

In other news, Director Roberto Mignone sold 200,000 shares of the company’s stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $24.11, for a total transaction of $4,822,000.00. Following the completion of the transaction, the director directly owned 495,000 shares of the company’s stock, valued at approximately $11,934,450. This represents a 28.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.49% of the stock is owned by company insiders.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Howard Bailey Securities LLC grew its holdings in Teva Pharmaceutical Industries by 3.5% in the third quarter. Howard Bailey Securities LLC now owns 14,451 shares of the company’s stock valued at $292,000 after purchasing an additional 494 shares during the last quarter. ASR Vermogensbeheer N.V. raised its stake in shares of Teva Pharmaceutical Industries by 1.6% during the 3rd quarter. ASR Vermogensbeheer N.V. now owns 31,915 shares of the company’s stock worth $645,000 after buying an additional 515 shares during the last quarter. CIBC Private Wealth Group LLC boosted its position in shares of Teva Pharmaceutical Industries by 15.5% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,020 shares of the company’s stock worth $81,000 after buying an additional 540 shares in the last quarter. Retirement Planning Co of New England Inc. grew its stake in Teva Pharmaceutical Industries by 1.8% in the 3rd quarter. Retirement Planning Co of New England Inc. now owns 33,230 shares of the company’s stock valued at $671,000 after acquiring an additional 588 shares during the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its stake in Teva Pharmaceutical Industries by 0.5% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 118,209 shares of the company’s stock valued at $1,981,000 after acquiring an additional 615 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.